Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1 D. CozzolinoL. CoppolaR. Torella PHARMACODYNAMICS Pages: 491 - 497
Lowering effects of four different statins on serum triglyceride level A. BranchiA. M. FiorenzaD. Sommariva PHARMACODYNAMICS Pages: 499 - 502
Delivery outcome after the use of antidepressants in early pregnancy A. EricsonB. KällénB.-E. Wiholm PHARMACODYNAMICS Pages: 503 - 508
Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults D. TavernerL. BickfordA. Tonkin PHARMACODYNAMICS Pages: 509 - 513
Clinical pharmacokinetics of ciprofloxacin in patients with major burns A. Lesne-HulinP. BourgetJ. Latarjet PHARMACOKINETICS AND DISPOSITION Pages: 515 - 519
Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing P. N. M. van HeiningenV. HatorpJ. H. G. Jonkman PHARMACOKINETICS AND DISPOSITION Pages: 521 - 525
Plasma ascorbic acid in patients undergoing chronic haemodialysis S. WangT. C. EideR. B. Sund PHARMACOKINETICS AND DISPOSITION Pages: 527 - 532
Adverse drug reactions and polypharmacy in the elderly in general practice L. J. G. VeehofR. E. StewartF. M. Haaijer-Ruskamp PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 533 - 536
Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use N. F. WieringaP. A. de GraeffP. A. de Graeff PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 537 - 544
Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? D. CapellàM. BrugueraJ.-R. Laporte LETTER TO THE EDITORS Pages: 545 - 546